Schedule 13D ownership disclosure
Evommune Inc
Common Stock, $0.0001 par value per share · CUSIP: 30054Y107
Event date: 2026-11-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.Reported CIK 0001346824
Shares: 3,494,638.00 · Class: 8.5%
- Peter KolchinskyReported CIK 0001384859
Shares: 3,494,638.00 · Class: 8.5%
- Rajeev ShahReported CIK 0001619841
Shares: 3,494,638.00 · Class: 8.5%
- RA Capital Healthcare Fund, L.P.Reported CIK 0001315082
Shares: 2,710,293.00 · Class: 6.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001346824-26-000259
- Form type
- SCHEDULE 13D/A
- Filer
- Evommune, Inc.
- CIK
- CIK 2044725
- Filed
- Nov 10, 2026
- Reporting period
- Nov 06, 2026
- Description
- Schedule 13D beneficial ownership